Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study
Cancer Research and Treatment. 2018;50(2):488-494 
Treatment for Non-clear Cell Renal Cell Carcinoma
Renal Cell Carcinoma. 2017;319-332
Papillary Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma Arising in a Single Kidney
BJUI. 2012;
Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label Multicenter Single-Arm Phase II Study
Clinical Lung Cancer. 2013;14(4):356-363
A multicenter phase II trial of axitinib in patients with recurrent or metastatic non-clear cell renal cell carcinoma who had failed prior treatment with temsirolimus
Clinical Genitourinary Cancer. 2018;
Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study
Clinical Genitourinary Cancer. 2009;7(3):E58-E65
T2 CLEAR CELL RENAL CELL CARCINOMA IS A RARE ENTITY: A STUDY OF 120 CLEAR CELL RENAL CELL CARCINOMAS
The Journal of Urology. 2005;174(4):1199-1202
Reintroducing Pazopanib Reverses the Primary Resistance of Nivolumab in a Patient With Metastatic Clear-cell Renal Cell Carcinoma
Clinical Genitourinary Cancer. 2018;16(2):114-116
An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology. 2013;8(12):1529-1537
Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy
Yearbook of Oncology. 2008;2008:219-221